Chi-Med Expected To Double Revenue By 2015, Backed By Urbanization, Healthcare Reform And TCM Performance in China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - UK-listed Chinese healthcare company Chi-Med is expected to double its current revenues of $111 million in the next five years, backed by rapid growth in traditional Chinese medicine and consumer products, U.S. investment banking firm Piper Jaffray said in an Aug. 4 research note
You may also be interested in...
A Closer Look: Hutchison MediTech TCM Deal With Nestle Reaches Into Pharma Development
A new joint venture between Nestle Health Science and Chi-Med covering nutritional and medicinal products derived from botanical plants also includes Phase III drug HMPL-004, ending the Chinese R&D firm’s long search for a partner.
Japanese Firm Mitsui Invests In China's Hutchison MediPharma; First Step Toward An IPO?
SHANGHAI - Hutchison MediPharma, one of China's leading biotechs, announced Nov. 8 that Tokyo-based venture capital firm Mitsui had acquired a 12.2 percent stake in the company for $12.5 million, generating speculation among China watchers that it could be a first step toward self-funding and an eventual IPO for Hutchison
Japanese Firm Mitsui Invests In China's Hutchison MediPharma; First Step Toward An IPO?
SHANGHAI - Hutchison MediPharma, one of China's leading biotechs, announced Nov. 8 that Tokyo-based venture capital firm Mitsui had acquired a 12.2 percent stake in the company for $12.5 million, generating speculation among China watchers that it could be a first step toward self-funding and an eventual IPO for Hutchison